|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
108.51(B) |
Last
Volume: |
353,858 |
Avg
Vol: |
760,830 |
52
Week Range: |
$692.45 - $1027.67 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
190,573 |
260,057 |
310,224 |
468,208 |
Total Sell Value |
$187,100,890 |
$251,782,343 |
$293,354,301 |
$403,868,951 |
Total People Sold |
7 |
14 |
16 |
18 |
Total Sell Transactions |
17 |
46 |
66 |
127 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Stahl Neil |
EVP Research and Development |
|
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,926 |
53,883 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-12-03 |
4 |
D |
$632.45 |
$31,845,122 |
D/D |
(50,352) |
50,957 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-12-03 |
4 |
OE |
$179.13 |
$12,986,925 |
D/D |
72,500 |
101,309 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-11-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,605 |
4,605 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2021-11-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,605 |
28,809 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2021-11-19 |
4 |
D |
$651.96 |
$234,142,959 |
D/D |
(359,137) |
465,922 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2021-11-19 |
4 |
OE |
$179.13 |
$115,030,120 |
D/D |
520,313 |
651,568 |
|
- |
|
Sing George L |
Director |
|
2021-11-18 |
4 |
S |
$650.00 |
$2,600,000 |
D/D |
(4,000) |
32,858 |
|
-7% |
|
Landry Robert E |
EVP Finance CFO |
|
2021-11-17 |
4 |
AS |
$645.08 |
$439,299 |
D/D |
(681) |
25,986 |
|
9% |
|
Sing George L |
Director |
|
2021-11-16 |
4 |
S |
$650.00 |
$487,500 |
I/I |
(750) |
1,000 |
|
-8% |
|
Sing George L |
Director |
|
2021-11-16 |
4 |
S |
$650.00 |
$3,937,580 |
D/D |
(6,000) |
36,858 |
|
-8% |
|
Landry Robert E |
EVP Finance CFO |
|
2021-11-16 |
4 |
D |
$651.97 |
$2,000,896 |
D/D |
(3,069) |
26,667 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2021-11-16 |
4 |
OE |
$399.66 |
$1,498,725 |
D/D |
3,750 |
29,736 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2021-11-16 |
4 |
AS |
$642.76 |
$4,638,263 |
D/D |
(7,167) |
55,705 |
|
8% |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2021-11-16 |
4 |
S |
$652.20 |
$4,452,194 |
D/D |
(6,778) |
26,931 |
|
-8% |
|
Murphy Andrew J |
EVP Research |
|
2021-11-15 |
4 |
D |
$641.50 |
$6,037,798 |
D/D |
(9,412) |
62,872 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2021-11-15 |
4 |
OE |
$52.03 |
$862,605 |
D/D |
16,579 |
72,284 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2021-11-15 |
4 |
D |
$641.50 |
$11,689,413 |
D/D |
(18,222) |
33,709 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2021-11-15 |
4 |
OE |
$270.43 |
$6,760,750 |
D/D |
25,000 |
51,931 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2021-11-01 |
4 |
AS |
$640.00 |
$640,000 |
D/D |
(1,000) |
17,038 |
|
4% |
|
Mccourt Marion |
EVP Commercial |
|
2021-11-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
18,038 |
|
- |
|
Ryan Arthur F |
Director |
|
2021-11-01 |
4 |
AS |
$638.62 |
$64,252 |
D/D |
(100) |
23,091 |
|
4% |
|
Vagelos P Roy |
Director |
|
2021-10-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
347 |
141,630 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2021-10-01 |
4 |
AS |
$576.75 |
$576,750 |
D/D |
(1,000) |
17,038 |
|
12% |
|
Mccourt Marion |
EVP Commercial |
|
2021-10-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
18,038 |
|
- |
|
2428 Records found
|
|
Page 20 of 98 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|